Overview

Stop Hep B @ Birth

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Single arm, prospective open-label study of a care model consisting of two components: Component I aims to achieve high coverage of interventions to prevent maternal-to-child transmission of hepatitis B virus: antenatal tenofovir, and timely newborn administration of hepatitis B birth dose vaccine and hepatitis B immune globulin; Component II aims to achieve high coverage of screening, vaccination, and anti-viral therapy for HBV among household members of women with chronic HBV infection.
Phase:
N/A
Details
Lead Sponsor:
Myanmar Liver Foundation
Treatments:
Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Tenofovir